Transglutaminases are a family of Cadependent enzymes involved in various biological events. Circulating transglutaminase (factor XIIIa) is decreased in blood of patients with inflammatory bowel diseases.
There is evidence that factor XIIIa and tissue type transglutaminase, present in cell cytosol, bind to various proteins of the extracellular matrix. This study examined the value of serum transglutaminase assay in the treatment and follow up of Crohn's disease and then investigated the intestinal location of both forms of transglutaminases by immunohistochemistry in normal and abnormal tissues. Serum transglutaminase activity was assayed in 36 patients with active Crohn's disease (CDAI>150). Eighteen patients were studied prospectively from relapse into remission. A significant inverse correlation (p<0.001) was found between circulating transglutaminase and Crohn's disease activity index; a correlation was also found between serum transglutaminase and serum orosomucoid (p<0.01) and C reactive protein (p<0.01). Patients were prospectively studied until clinical remission showed improvement in both their CDAI score mean (SD) (230 (46) to 72 (34) , p<O .Ol) and transglutaminase activity mean (SD) (0.61 (0.12) to 0 93 (0.13) mU/ml, p<0.01). The immunohistochemistry assessment showed a colocalisation of factor XIIIa and tissue transglutaminase to the extracellular matrix of damaged tissues. In conclusion, these data confirm the value of serum transglutaminase assay as marker of Crohn's disease activity, extend the utility of serum transglutaminase assay to follow up of the disease, and emphasised the role of different types of transglutaminases in extracellular matrix assembly in the damaged tissues. Serum transglutaminase and haematological parameters were also evaluated in 18 patients studied prospectively during the active phase (CDAI> 150) and subsequent inactive phase (CDAI< 150) of the disease.
In the four patients undergoing surgery, serum transglutaminase concentrations and haematological parameters were evaluated before and 15 and 60 days after bowel resection.
The control group included 21 patients with disease other than inflammatory bowel disease but also leading to debility (liver cirrhosis, cardiovascular disorders, non-intestinal malignancies). Serum transglutaminase from 38 healthy subjects was also assayed. Immunohistochemistry Routinely processed, formalin fixed, and paraffin wax embedded specimens were taken from the ileum of four Crohn's disease patients and from the colon of four Crohn's disease patients who were operated on during 1993 and were drawn from the files of the Institute of Pathologic Anatomy at the School of Medicine, Naples. Uninvolved bowel of patients undergoing surgery for carcinoma or large polyps were used as a 'normal' control tissue. Immunohistochemical examination was performed on normal and abnormal ileum and colon using either anti-tissue transglutaminase or anti-FXIIIa antibodies. The ematoxilineosine stained specimens were immunoprobed with the antibodies and visualised using a peroxidase anti-peroxidase system,29 according to the manufacturer's directions. 
Statistics
Student's t test and linear regression were used to perform statistical evaluations. Results, expressed as mean (SD), were considered statistically significant when p<0 05. Table I shows the clinical and haematological characteristics of Crohn's disease patients. As shown, the mean CDAI score in the total group of patients was 233 (range 169-366), while the mean (SD) serum transglutaminase activity was 0.62 (0 11). When patients were grouped according to localisation of the disease, serum transglutaminase concentrations were found to be significantly higher in patients with ileitis (transglutaminase=0.72 (0 14) mU/ml) compared with patients with ileocolitis/colitis (transglutaminase=0.50 (0.08); p<0 05). No differences were found, however, between CDAI scores from patients with ileitis versus ileocolitis/colitis (228 (37) v 236 (57) respectively) (Fig 1) .
Results

Patients
When the whole group of patients was considered, a strong correlation (r= -0'60; p<O.OOl) was found between serum transglutaminase and CDAI scores (Fig 2) . A significant correlation was also found between circulating transglutaminase and serum orosomucoid (r=-0-55; p<0Q01) and C reactive protein (r=-0.52; p<001).
Eighteen patients were followed up until remission, which mainly occurred after 4 1 months (range 1-9). Their CDAI scores improved from 230 (46) to 72 (34) during the active and inactive phases respectively (p<0.01). Furthermore, the decreased circulating transglutaminase values seen during the active phase returned toward normal values during the subsequent inactive phase of the disease (0.61 (0.12) v 0 93 (0.13), p<0 01) (Fig 3) . In the four patients who had intestinal resection, the CDAI significantly decreased 15 days after surgery, while increased serum transglutaminase was seen only at 60 days (Table II) . As expected, the mean serum enzyme values in the control and healthy volunteer groups fell to within the normal range (1.80 (0.57) mU/ml).7
Western blotting Antiserum raised against FXIIIa recognised purified FXIIIa and cross reacted with tissue transglutaminase on western blots as shown in Fig 4 (lane 1 and 2) . Anti-tissue transglutaminase antiserum showed a specific immunoreactivity for tissue transglutaminase (lane 4), while did not recognise FXIIIa (lane 3).
Immunohistochemical studies Tissue transglutaminase antibody -the staining pattern showed that the enzyme is present in the basal region of the crypts in normal ileum (Fig 5 (A) ) while strongly positive areas involving the whole crypt and to a lesser extent the extracellular matrix appeared in ileal Crohn's disease (Fig 5 (B) ). In normal colon the positivity to tissue transglutaminase antibody was found along the crypt surface (Fig 5  (C) ). In colonic Crohn's disease the staining pattern showed that the enzyme is mainly localised to the extracellular matrix but also within the crypts (Fig 5 (D) ). 
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FXIIIa antibody -the positivity to FXIIIa antibody found in normal ileum (Fig 6 (A) ) and colon Fig 6 (C) ) was similar to that obtained with tissue transglutaminase antibody. Immunostaining in ileal (Fig 6 (B) ) and colonic (Fig 6 (D) Figure 6A the intestine,31 using proteins of the extracellular matrix such as fibronectin and collagen, which are suitable substrates for the enzyme.15 32 60 days. It is possible that the delayed normalisation of serum transglutaminase when compared with CDAI scores could be related to a slow reconstitution of the normal transglutaminase circulating pool or to the local need of the enzyme for the mucosal morphofunctional recovery after intestinal resection, or both.37
In conclusion our data further confirm the usefulness of serum transglutaminase assay as a marker of Crohn's disease activity, extend the utility of serum transglutaminase assay to the follow up of the disease, and underline the role of different types of transglutaminases in the extracellular matrix assembly in the damaged tissue.
